Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Advantage

Pulmonary Disease, Chronic Obstructive (COPD) Clinical Trial

Official title:
A Randomized, Open-label, Cross-over Study Comparing the Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): The Advantage Study

Status Completed

Clinical Trial Summary

The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Pulmonary Disease, Chronic Obstructive (COPD)

Clinical Trial Details

NCT number	NCT02551224
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	N/A
Start date	September 2015
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03269721` - COPD-Related Physiology and the Brain
Active, not recruiting	`NCT01976117` - E-nose Utility in the Diagnosis of Bacterial Infection in COPD	N/A
Active, not recruiting	`NCT05915182` - Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
Completed	`NCT01580072` - Telemonitoring of Patients With COPD in Carinthia	N/A
Completed	`NCT02596009` - Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices	Phase 4